Sustained remission of multicentric castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody

Molecular Cancer Therapeutics

Volumn 11, Issue 8, 2012, Pages 1623-1626

  Galeotti, Caroline ^a   Boucheron, Adeline ^a   Guillaume, Séverine ^a   Koné Paut, Isabelle ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; INTERLEUKIN 6 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; VINBLASTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CHILD; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GROWTH RATE; HUMAN; HYPERGAMMAGLOBULINEMIA; MALE; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84864881812     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0972     Document Type: Article

References (15)

1. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic signi ficance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7. (Pubitemid 19227448)
2. Hsu SM, Waldron JA, Xie SS, Barlogie B. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993;24:833-9. (Pubitemid 23238961)
3. Kinney MC, Hummell DS, Villiger PM, Hourigan A, Rollins-Smith L, Glick AD, et al. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease. J Clin Immunol 1994;14:382-90.
4. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-inter-leukin- 6 receptor antibody therapy. Blood 2000;95:56-61. (Pubitemid 30017224)
5. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32. (Pubitemid 41510733)
6. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28:3701-8.
7. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836-9. (Pubitemid 351664423)
8. Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003;102:2786 -8.
9. Larroche C, Cacoub P, Godeau P. [Castleman's disease]. Rev Med Interne 1996;17:1003-13.
10. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330: 602-5. (Pubitemid 24065794)
11. Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Kone-Paut I. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol 2008;30:920-4.
12. Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1: 193-200.
13. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67: 1516-23.
14. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum inter-leukin- 6 (IL-6) and soluble IL-6 receptor after administration of an anti- IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
15. Harada N, Sayama K, Tanaka K, Hasegawa N, Okamoto S, Hayashi Y, et al. [Long-term treatment with a humanized anti-interleukin-6 receptor antibody (tocilizumab), improving interstitial pneumonia in a patient with multicentric Castleman disease]. Nihon Kokyuki Gakkai Zasshi 2010;48:145- 50.